Trials / Completed
CompletedNCT03991494
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Pamiparib Following Single Oral Dose Administration in Patients With Advanced and/or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase. The research phase (Part 1) of the study will assess the disposition of a single oral dose of \[14C\]-pamiparib. In the treatment phase (Part 2) participants will be allowed to have continued access to pamiparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-pamiparib | During the treatment phase, pamiparib 60 mg administered orally twice daily |
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2019-10-21
- Completion
- 2020-08-05
- First posted
- 2019-06-19
- Last updated
- 2021-09-27
- Results posted
- 2021-09-27
Locations
2 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03991494. Inclusion in this directory is not an endorsement.